Haris Riaz

Haris Riaz

Auto-generated profile, based on publicly available information

Haris Riaz

Heart and Vascular Institute, Cleveland Clinic, Ohio

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2018 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
HRHaris Riaz
Haris Riaz
MKMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
TSTariq Jamal Siddiqi
Tariq Jamal Siddiqi
MUMuhammad Shariq Usman
Muhammad Shariq Usman
NSNishant Shah
Nishant Shah
HAHaitham Ahmed
Haitham Ahmed
Coronary artery disease (CAD) and its ensuing complications, including myocardial infarction and heart failure, continue to be the leading cause of morbidity and mortality in the developed world and increasingly so in the developing world.1-3 Dyslipidemia has consistently been shown to be associated with atherosclerosis. The mechanistic link between dyslipidemia and atherogenesis is supported by a large number of studies demonstrating a correlation between levels of low-density lipoprotein cholesterol and major adverse cardiovascular events.4,5 Further support is provided by studies with pharmacological agents, including statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors, which reduce low-density lipoprotein cholesterol and improve cardiovascular disease (CVD) outcomes when used for either primary or secondary prevention.6,7

6 December 2018 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
PDF file
HRHaris Riaz
Haris Riaz
SKSafi U Khan
Safi U Khan
HRHammad Rahman
Hammad Rahman
NSNishant P Shah
Nishant P Shah
EKEdo Kaluski
Edo Kaluski
SNSteven E Nissen
Steven E Nissen
Background: The effects of increasing high-density lipoprotein cholesterol on cardiovascular outcomes remain uncertain. Design: We conducted a meta-analysis to investigate the effects of high-density lipoprotein cholesterol modifiers (niacin, fibrates and cholesteryl ester transfer protein inhibitors) on cardiovascular outcomes. Methods: Thirty-one randomized controlled trials (154,601 patients) with a follow-up of 6 months or more and a sample size of 100 or more patients were selected using MEDLINE, EMBASE and CENTRAL database (inception January 2018). Results: High-density lipoprotein cholesterol modifiers had no statistically significant effect on cardiovascular mortality in terms of relative risk (RR) (RR 0.94, 95% confidence interval (CI) 0.89–1.00, P = 0.05, I2 = 13%) or absolute risk (risk difference −0.0001, 95% CI −0.0014, 0.0011, P = 0.84, I2 = 28%). High-density lipoprotein cholesterol modifiers reduced the RR of myocardial infarction (RR 0.87, 95% CI 0.82–0.93, P < 0.001, I2 = 37%). This significant effect was derived by the use of fibrates (RR 0.80, 95% CI 0.73–0.87, P < 0.001, I2 = 22%) and meta-regression analysis showed that this benefit was consistent with an absolute reduction in low-density lipoprotein cholesterol. High-density lipoprotein cholesterol modifiers had no effect on stroke (RR 1.00, 95% CI 0.93–1.09, P = 0.94, I2 = 25%) or all-cause mortality (RR 1.02, 95% CI 0.97–1.08, P = 0.48, I2 = 49%). Meta-regression analyses failed to demonstrate a significant association of pharmacologically increased high-density lipoprotein cholesterol with key endpoints. In studies with background statin therapy, high-density lipoprotein cholesterol modifiers had no statistically significant impact on cardiovascular mortality, myocardial infarction, stroke or all-cause mortality ( P > 0.05). Conclusion: The use of high-density lipoprotein cholesterol modifying treatments had no significant effect on cardiovascular mortality, stroke or all-cause mortality. The beneficial effect on myocardial infarction was lost when drugs were used with statin therapy.

1 September 2017 in The American Journal of Cardiology
Verified
Journal Article
Closed access
HRHaris Riaz
Haris Riaz
AKAbdur Rahman Khan
Abdur Rahman Khan
MKMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
KRKarim Abdur Rehman
Karim Abdur Rehman
SAShehab Ahmad Redha Alansari
Shehab Ahmad Redha Alansari
RKRichard A. Krasuski
Richard A. Krasuski

1 December 2015 in The American Journal of Cardiology
Verified
Journal Article
Closed access
HRHaris Riaz
Haris Riaz
SRSajjad Raza
Sajjad Raza
MKMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
IRIrbaz Bin Riaz
Irbaz Bin Riaz
RKRichard A. Krasuski
Richard A. Krasuski

1 May 2016 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
HRHaris Riaz
Haris Riaz
SAShehab Ahmad Redha Alansari
Shehab Ahmad Redha Alansari
MKMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
TRTalha Riaz
Talha Riaz
SRSajjad Raza
Sajjad Raza
RKRichard A. Krasuski
Richard A. Krasuski
Background—: The American College of Cardiology guidelines recommend 3 months of anticoagulation after replacement of the aortic valve with a bioprosthesis. However, there remains great variability in the current clinical practice and conflicting results from clinical studies. To assist clinical decision making, we pooled the existing evidence to assess whether anticoagulation in the setting of a new bioprosthesis was associated with improved outcomes or greater risk of bleeding. Methods and Results—: We searched the PubMed database from the inception of these databases until April 2015 to identify original studies (observational studies or clinical trials) that assessed anticoagulation with warfarin in comparison with either aspirin or no antiplatelet or anticoagulant therapy. We included the studies if their outcomes included thromboembolism or stroke/transient ischemic attacks and bleeding events. Quality assessment was performed in accordance with the Newland Ottawa Scale, and random effects analysis was used to pool the data from the available studies. I 2 testing was done to assess the heterogeneity of the included studies. After screening through 170 articles, a total of 13 studies (cases=6431; controls=18210) were included in the final analyses. The use of warfarin was associated with a significantly increased risk of overall bleeding (odds ratio, 1.96; 95% confidence interval, 1.25–3.08; P <0.0001) or bleeding risk at 3 months (odds ratio, 1.92; 95% confidence interval, 1.10–3.34; P 3 months (odds ratio, 1.12; 95% confidence interval, 0.80–1.58; P =0.79). Conclusions—: Contrary to the current guidelines, a meta-analysis of previous studies suggests that anticoagulation in the setting of an aortic bioprosthesis significantly increases bleeding risk without a favorable effect on thromboembolic events. Larger, randomized controlled studies should be performed to further guide this clinical practice.

14 October 2019 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Closed access
PDF file
HRHaris Riaz
Haris Riaz
SKSafi U Khan
Safi U Khan
NLNoman Lateef
Noman Lateef
STSwapna Talluri
Swapna Talluri
MKMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
MDMilind Y Desai
Milind Y Desai
Recently, there has been an increasing interest in targeting inflammation to reduce major adverse cardiovascular events (MACE) in patients with cardiovascular risk. Statins, PCSK9 inhibitors, and ezetimibe have been shown to reduce MACE owing to reduction in low-density lipoproteins cholesterol (LDL-c). Herein, we investigate whether the intensity of these agents is associated with (i) discernible reduction in inflammation measured by the levels of high-sensitivity C-reactive protein (hsCRP); (ii) reduction in MACE; (iii) if there is an association between the baseline hsCRP and MACE. Electronic databases were searched for randomized controlled trials (RCTs) that compared statins, ezetimibe, PCSK9 inhibitors with placebos/active controls and reported MACEs and hsCRP (mg/L). Studies were stratified based on baseline hsCRP (3) with subgroup analysis conducted across each stratum. Fourteen RCTs including 133 109 patients randomized into more intensive therapy (MIT) and less intensive therapy were selected. Meta-analysis did not demonstrate any significant differences between use of MIT and hsCRP levels (mean difference, −0.02; CI, −0.06, 0.02; P = 0.31). The MIT significantly reduced the risk of MACE (RR, 0.82; CI, 0.75, 0.91; P < 0.001). The relative risk and absolute risk remained consistent across the strata. However, there was a 0.5% statistically significant absolute risk reduction in all-cause mortality in patients with higher hsCRP (RD, −0.005; CI, −0.009, −0.001; P = 0.01). Overall, LDL-c lowering therapies reduce relative risk of MACEs particularly in patients with higher baseline hsCRP. However, there appears to be a residual inflammatory risk despite the use of contemporary lipid lowering agents.